Plain-English translation of NCT07709520 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing / tablets in people who have chronic hepatitis B and are already taking antiviral medications that have successfully suppressed their virus. Researchers want to see if this new medication is safe and whether it can work alongside current treatments to help manage the disease better.
Many people with hepatitis B need to take antiviral medications for life, and some may not respond well enough to current treatments alone. This study is exploring whether this new medication could offer an additional option to help more patients achieve better control of their infection.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either receive the new medication or a placebo (dummy pill) — neither you nor the researchers will know which one you get at first. You'll take tablets by mouth as instructed and attend clinic visits for blood tests to monitor your liver function and virus levels. The study will track your safety and how well the treatment works over a set period of time.
AI-generated summary from trial data · Aug 13, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fujian Akeylink Biotechnology Co., Ltd.
Enrollment target
~80 participants
Started
July 2026
Primary completion
October 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
35 Years – 65 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
zhang tianxiang
Fujian Akeylink Biotechnology Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.